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In 2004, coronary heart disease (CHD) affected an
estimated 15.8 million people in the USA and was
responsible for one of every ﬁve deaths, making it
the single largest cause of mortality in American men
and women (1). In the UK, CHD causes over
105,000 deaths annually; approximately 21% of
deaths in men and 15% of deaths in women (2). The
prevalence of CHD increases with age, particularly
after age 55 years in men and age 65 years in
women, although many younger adults experience
acute coronary events secondary to the development
of premature CHD. Each year approximately 700,000
Americans have their ﬁrst coronary event, and
500,000 have a recurrent event. Those who survive
the incident event have substantially higher risk of
recurrent coronary events and sudden death, as well
as heart failure and stroke. In addition to increasing
morbidity and mortality, CHD places a substantial
economic burden on society, with total annual costs
in the USA estimated at $151.6 billion (1). This total
includes $83.6 billion in direct medical expenditures
and $68.0 billion in lost productivity because of
CHD morbidity and premature mortality. When
other types of cardiovascular disease are included,
the prevalence rises to 79.4 million people and the
total annual cost to $431.8 billion (1). Similarly,
CHD costs the healthcare system in the UK around
£3500 million annually. Hospital care for people who
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SUMMARY
Atherosclerosis is a chronic, progressive, inﬂammatory disease with a long asymp-
tomatic phase. Disease progression can lead eventually to the occurrence of acute
cardiovascular events such as myocardial infarction, unstable angina pectoris and
sudden cardiac death. While the disease is still in a subclinical stage, however, the
presence of atherosclerosis can be identiﬁed by several methods, including coro-
nary angiography, intravascular ultrasonography, B-mode ultrasonography, com-
puted tomography and magnetic resonance imaging. Based on the results of
imaging studies, statin therapy can slow, halt or even reverse the progression of
atherosclerotic disease, depending on the intensity of treatment. Whether to screen
and treat patients for subclinical atherosclerosis remains controversial. Although
atheromatous plaque burden reduction has not yet been deﬁnitively correlated with
signiﬁcant decreases in risk for acute coronary events in asymptomatic patients,
statin therapy contributes signiﬁcantly to the risk reduction observed in clinical tri-
als in patients with and without overt coronary disease.
Review Criteria
Atherosclerotic disease in both its subclinical and
clinically established phases is widely prevalent
throughout the world. A variety of imaging
modalities (B-mode ultrasonography, intravascular
ultrasonography, computed tomography, magnetic
resonance imaging) have been developed to detect
and better deﬁne the burden of atherosclerotic
lesions in individuals at risk for cardiovascular
disease. Statin therapy has been shown to reduce
cardiovascular morbidity and mortality in a wide
spectrum of patient populations. It is becoming
increasingly apparent that statins also impact the
course of atherogenesis. The major controlled,
randomized studies evaluating the capacity of statin
therapy to positively impact the progression of
atherosclerotic disease are reviewed herein.
Message for the Clinic
Arterial imaging of both the carotid and coronary
vasculature can be used to further reﬁne risk based
on Framingham risk scoring. Statin therapy
favorably impacts rates of atherogenesis. High-dose
statin therapy and aggressive low-density
lipoprotein cholesterol lowering are associated with
atheromatous plaque stabilization and even
regression. If subclinical atherosclerotic disease is
detected, strong consideration should be given to
coupling lifestyle modiﬁcation with statin therapy,
irrespective of overall risk factor burden.
doi: 10.1111/j.1742-1241.2008.01804.x
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while buying and dispensing drugs accounts for a
further 16% (2).
Coronary heart disease is a clinical manifestation
of atherosclerosis, a chronic and progressive inﬂam-
matory disease. Atherosclerosis begins early in life.
Postmortem evaluation of hearts of young (mean
age, 22.1 years) men killed during the Vietnam con-
ﬂict demonstrated that almost 50% had some evi-
dence of coronary atherosclerosis (3). Similarly,
postmortem analysis of coronary vessels from teenag-
ers and young adults who died from other causes
showed evidence of early atherosclerotic lesions and,
in some cases, ﬁbrous plaques (4,5). In the latter two
studies, the extent of coronary atherosclerosis was
directly associated with ante-mortem concentrations
of low-density lipoprotein cholesterol (LDL-C) and
negatively associated with high-density lipoprotein
cholesterol (HDL-C). Although subclinical vascular
disease is asymptomatic, it can lead to both physical
and cognitive dysfunction if left untreated (6).
Atherogenesis
Atherogenesis begins at sites of endothelial injury.
Such injury may result from a variety of factors,
including increased local shear forces from hyperten-
sion, elevated plasma concentrations of LDL-C and
remnant lipoprotein particles, chemical toxins in cig-
arette smoke, low serum HDL-C and impaired
reverse cholesterol transport, insulin resistance, and
glycosylated end product formation in diabetes mell-
itus, among others (Table 1) (7–9). These factors
decrease endothelial cell production of nitric oxide,
thereby impairing vasodilatory capacity and the nor-
mal barrier and protective functions of the vascular
endothelium. As a result, LDL-C inﬁltrates the
subendothelial space, where it can be oxidatively
modiﬁed by a variety of enzymes (e.g. 5¢-lipoxygen-
ase, phospholipase A2 and myeloperoxidase) (10).
Dysfunctional endothelial cells express a number of
adhesion molecules (vascular cell adhesion molecule-
1, intercellular adhesion molecule-1) and selectins
that promote the binding of circulating monocytes
to vascular endothelial cells (10). Once attached,
monocytes are exposed to monocyte chemoattractant
protein-1, a chemokine that promotes the transmi-
gration of bound monocytes into the subendothelial
space. There is evidence that monocytes can access
the vessel wall via direct endothelial transcytosis or
between endothelial cells with impaired gap junc-
tional association (11). The production of monocyte
colony stimulating factor in the inﬂamed intima pro-
motes the differentiation of monocytes into macro-
phages. Macrophages exposed to modiﬁed LDL
express scavenger receptors (SRA, CD-36) that bind
and promote the internalisation of oxidised LDL and
a broad range of other particles and cell fragments
(8,10). As the macrophage progressively accumulates
more and more cholesterol, cytosolic lipid droplets
form, and the macrophage takes on the appearance
of a lipid-laden foam cell.
T-lymphocytes and other mediators of inﬂamma-
tion and immunity inﬁltrate the developing lesion
site from both the intimal and adventitial aspects of
the vessel wall (12). Once localised to the various
layers of the arterial wall, T cells can secrete inﬂam-
matory cytokines and growth factors, which in turn
provide a signal for smooth muscle cells to alter their
cytoskeleton, produce matrix metalloproteinases, and
migrate from the media into the intimal space, where
they proliferate and secrete extracellular matrix com-
ponents that form a ﬁbrous cap over the developing
lesion (8,10,13).
The cytokines released as part of the inﬂammatory
cascade stimulate production of interleukin-6, which
in turn stimulates the production of C-reactive pro-
tein (CRP) and other acute-phase reactants (10). It is
important to recognise that the ongoing inﬂamma-
tory response in the vascular wall continues to pro-
vide signals for further LDL uptake and leucocyte
inﬁltration, creating conditions for further growth of
the atherosclerotic lesion (9). Over time, the athero-
sclerotic lesion continues to expand at its base via
the same mechanisms that led to formation of the
initial fatty streak.
The stability of the advanced atherosclerotic lesion
or plaque depends on its cellular and extracellular
contents. Plaques with small lipid cores, thick ﬁbrous
caps, few inﬂammatory cells and a preponderance of
smooth muscle cells are typically stable; conversely,
those with large lipid cores, thin ﬁbrous caps,
numerous macrophages and relatively few smooth
muscle cells are most likely to rupture (9,14). Acti-
vated macrophages in the developing plaque secrete
matrix metalloproteinases that degrade and weaken
the matrix component of the ﬁbrous cap. They also
Table 1 Risk factors contributing to atherosclerosis
Genetics (family history)
Diabetes mellitus
Obesity
Cigarette smoking
High serum levels of low-density lipoprotein cholesterol
Low serum levels of high-density lipoprotein cholesterol
Physical inactivity
Hypertension
Age (> 55 years in men, > 65 years in women)
Systemic inﬂammatory states
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proliferation and matrix production and promote
smooth muscle cell apoptosis (14). The inﬂammatory
process can be kept in balance by the actions of
smooth muscle cells, which provide the matrix com-
ponents necessary to strengthen and stabilise the
ﬁbrous cap.
Plaque rupture usually occurs at the base of the
ﬁbrous cap, which is usually thin and contains rela-
tively few smooth muscle cells and many inﬂamma-
tory cells. When the plaque ruptures, platelets and
coagulation factors in circulating blood are exposed
to the thrombogenic contents of the plaque’s extra-
cellular matrix and lipid core, including collagen,
phospholipids and tissue factor (10,13). Thereafter,
the disrupted plaque serves as a scaffold to allow
platelet aggregation and coagulation. The formation
of thrombin, subsequent conversion of ﬁbrinogen to
ﬁbrin, and release of von Willebrand factor from
activated platelets creates a cross-linked network that
allows a thrombus to form. The thrombus size
depends on the extent of plaque rupture as well as
activity of the endogenous ﬁbrinolytic pathway.
When sufﬁciently large, the thrombus can either par-
tially or completely occlude the coronary vessel
lumen and precipitate an acute coronary event (9).
Atheromatous plaque burden
Many plaque ruptures are clinically silent but can be
detected on postmortem assessment as breaks in the
ﬁbrous cap associated with evidence of healing (15).
In a cohort of 142 men who died of sudden coro-
nary death, 86 hearts (61%) had evidence of healed
silent ruptures (15). Notably, however, acute plaque
rupture occurred commonly in arteries with evidence
of previously healed silent ruptures that demon-
strated greater luminal narrowing than in arteries
without these healed ruptures. Moreover, arterial
luminal narrowing increased with the numbers of
healed sites of previous plaque rupture. Immuno-his-
tochemical analysis revealed that smooth muscle pro-
liferation was increased at healed rupture sites,
suggesting that the occurrence and healing of silent
plaque ruptures contributes to further expansion of
atherosclerotic plaque (15).
The prevalence and extent of atherosclerosis
increase with age. In the Framingham risk assess-
ment, age is used as a surrogate for coronary plaque
burden, but plaque burden is the true risk factor for
CHD-related morbidity and mortality (16). Because
plaque burden can vary among individuals at any
given age, accurate measurement of subclinical ath-
erosclerosis may provide a better method for predict-
ing risk for acute cardiovascular events.
Markers of inﬂammation are regarded as surro-
gates of asymptomatic atherosclerosis, inasmuch as
inﬂammation plays a central role in the atherogenic
process. Higher CRP levels have been consistently
associated with increased risk for major cardiovascu-
lar events across numerous populations and have
also been shown to add prognostic information to
LDL-C levels and Framingham risk scores (17).
However, the role of CRP as an aetiologic factor in
atherosclerosis is not yet clear (18). In the Dallas
Heart Study, a population-based cohort of nearly
3400 subjects aged 30–65 years (19), higher CRP lev-
els were associated with a modest increase in the
prevalence of subclinical atherosclerosis as detected
by electron-beam computed tomography (EBCT) or
magnetic resonance imaging (MRI), but this associa-
tion was not independent of traditional cardiovascu-
lar risk factors. The authors concluded that CRP is a
poor predictor of atherosclerosis disease burden. In
the Inﬂammation and Carotid Artery – Risk for Ath-
erosclerosis Study (20), higher CRP levels were asso-
ciated with morphologic features of progressive
carotid atherosclerosis in asymptomatic CHD
patients. Whether or not CRP proves to be causally
related to the atherothrombotic process, it appears to
be a sensitive biomarker for quantiﬁcation of cardio-
vascular risk (21). The Justiﬁcation for the Use of
statins in Primary prevention: an International Trial
Evaluating Rosuvastatin (JUPITER) (22), was
designed to determine whether statin therapy reduces
vascular event rates in persons with normal levels of
LDL-C and elevated levels of CRP. In an interim
analysis by this study’s Data Safety and Monitoring
Board, the JUPITER trial has been terminated earlier
than expected because rosuvastatin therapy demon-
strated signiﬁcant capacity to reduce both mortality
and cardiovascular morbidity compared to placebo.
Prevalence of subclinical
atherosclerosis
Although the exact prevalence of subclinical athero-
sclerosis is undetermined, it is noteworthy that 50%
of men and 64% of women in the USA who die sud-
denly from CHD have no prior manifestation of dis-
ease, and the majority of these individuals were not
considered to be at high risk according to Framing-
ham risk stratiﬁcation. In an assessment of more
than 5000 adults aged ‡ 65 years participating in the
Cardiovascular Health Study, the prevalence of sub-
clinical atherosclerotic disease was 36% in women
and 38.7% in men and increased with age (23). In a
later study, 318 asymptomatic subjects were ran-
domly sampled from the Framingham Offspring
Study cohort based on strata of sex, age and
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revealed that 38% of women and 41% of men had
evidence of aortic atherosclerosis, and, again, plaque
burden increased with age group (24).
A plethora of studies have found increased preva-
lence of subclinical atherosclerosis as measured by
CT and⁄or carotid ultrasound in discrete population
groups without evidence of CHD, including post-
menopausal women (25), women with a family his-
tory of premature CHD (26), and European
Americans as compared with African Americans
(27), among others. It is apparent that metabolic dis-
orders contribute to subclinical atherosclerosis, which
has been identiﬁed in persons with impaired fasting
glucose (28), persons with the metabolic syndrome
(29–31), and those with diabetes mellitus (31–33).
Techniques for measuring subclinical
atherosclerosis
A variety of invasive and non-invasive techniques are
available to measure atherosclerosis and subclinical
atherosclerosis (Table 2). These techniques can ascer-
tain parameters such as luminal diameter or stenosis,
vessel wall thickness, plaque volume, and the speciﬁc
distribution and localisation of atherosclerotic
disease. Accordingly, although atherosclerosis may be
asymptomatic, it can be identiﬁed and quantiﬁed
within speciﬁc distributions of the vasculature.
Non-invasive techniques
B-mode ultrasonography can determine the com-
bined thickness of the arterial intimal and medial
layers, usually measured in the common carotid
artery (34). The carotid intima-media thickness
(IMT) reﬂects the diffuse thickening of the intimal
layer seen in atherosclerosis and has been validated
as a measure of the risk for cardiovascular events
(35) and atherosclerotic disease burden (36). High-
resolution MRI non-invasively evaluates plaque vol-
ume and composition, ﬁbrous cap integrity, and
lesion type. Consequently, it provides a measure of
both plaque burden and susceptibility to rupture
(37,38). Both B-mode ultrasound and high-resolu-
tion MRI are currently used only in clinical trial set-
tings and are not yet developed enough for
individual patient diagnostics. It remains to be estab-
lished how reproducible IMT measurements are out-
side of core laboratory settings.
Electron-beam CT, which is used clinically, mea-
sures coronary artery calciﬁcation. Coronary calcium
reﬂects plaque burden, because calcium deposits are
related to the lipid and apoptotic remnants of the
plaque (39). Coronary artery calciﬁcation is an
independent cardiovascular risk factor (40) that
adds prognostic information when considered in
conjunction with other risk factors (41) and when
used in patients with a 10-year CHD risk of > 10%
based on Framingham risk scoring (42). However,
although EBCT can localise coronary plaques within
the coronary tree and provide a quantitative mea-
sure of relative disease severity, it cannot be used to
ascertain the susceptibility of individual plaques to
rupture.
Contrast-enhanced multislice CT, also known as
MDCT, uses electrocardiogram-gated images to
quantify atherosclerotic calciﬁcation in the coronary
arteries (43,44). Because of its enhanced sensitivity, it
is generally used for detailed studies of the coronary
anatomy, whereas EBCT, which uses relatively little
radiation, is more often reserved for studies quantify-
ing coronary artery calciﬁcation.
Invasive techniques
Coronary angiography localises plaque and reveals
degrees of coronary luminal stenosis (as such, it pro-
vides a ‘lumenogram’). Although the presence and
number of high-grade stenoses are associated with
increased risk of future coronary events, angiography
cannot identify culprit lesions that are prone to rup-
ture and cause acute coronary syndromes (ACS)
(45). Intravascular ultrasound (IVUS), another
experimental technique, is an invasive procedure
made possible by the miniaturisation of ultrasound
transducers that can be placed at the tip of a coro-
nary catheter (46). Unlike coronary angiography,
Table 2 Comparison of techniques for identiﬁcation of subclinical atherosclerosis
Characteristic Coronary
angiography
Intravascular
ultrasound B-mode ultrasound
Magnetic resonance
imaging
Electron-beam c
omputed tomography
Invasive Yes Yes No No No
Primary measure Stenosis Plaque volume
and composition
Intimal-medial
thickness
Plaque volume
and composition
Coronary artery
calciﬁcation
Plaque composition No Yes No Yes No
Plaque burden No Yes No Yes Yes
Plaque vulnerability No Yes No Yes No
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vessel lumen, IVUS can quantify the size and compo-
sition of plaques along the entire thickness of the
vessel wall and, consequently, provides information
about lesion location and the magnitude of plaque
burden. IVUS can also identify ectatic plaque that is
not yet infringing on the arterial lumen. IVUS is not
a screening tool, however, and is currently used only
as an experimental technique.
The promise of these techniques is that a single
measurement can provide valuable information
about the distribution and localisation of subclini-
cal atherosclerosis. Serial measurements made over
time provide the opportunity to evaluate the
impact of risk factor treatment on atherosclerotic
disease progression and, perhaps, changes in risk
for ACS.
Predictive value of cardiovascular
imaging techniques
To determine whether carotid IMT improved predic-
tion of coronary events compared with the Framing-
ham Risk Score, Baldassarre et al. (47) studied 1969
dyslipidaemic patients considered to be at low or
intermediate risk who underwent carotid ultrasound
at a lipid clinic. Both the Framingham Risk Score and
the carotid IMT were independent predictors of out-
come (p < 0.04 for both), and the IMT signiﬁcantly
improved the predictive value of the Framingham
Risk Score (p = 0.04). Patients whose Framingham
scores placed them at intermediate risk were deter-
mined to be at high risk when their carotid IMT was
above the 60th percentile (men) or the 80th percen-
tile (women) of the maximum IMT distribution.
Two recently published meta-analyses were
conducted to determine the extent to which
surrogate markers for atherosclerosis predict future
cardiovascular end-points. Simon et al. (48) used
published data of prospective studies of subclinical
disease to calculate the incidence of cardiovascular
end-points associated with subclinical atherosclerosis
as identiﬁed by carotid IMT, carotid ultrasound,
elevated coronary artery calcium on CT examination,
decreased ankle–arm index pressure assessed by
Doppler, or pulse wave velocity assessed by meca-
nography. They found that while the yearly incidence
of coronary events was < 1% in the absence of ath-
erosclerosis, it increased to > 1–3% in the presence
of atherosclerosis, depending on the marker tested.
The authors concluded that detection of subclinical,
asymptomatic disease is a worthwhile screening test
for predicting future cardiovascular events (48).
Lorenz et al. (35) performed a systematic review
and meta-analysis of eight studies examining the
association between carotid IMT and vascular events.
Using random effects models, they found that
adjusted for age and sex, the relative risk of a myo-
cardial infarction per one standard deviation differ-
ence in common carotid artery IMT was 1.26 [95%
conﬁdence interval (CI): 1.21–1.30] and per 0.10-
mm difference it was 1.15 (95% CI: 1.12–1.17). The
relative risk for stroke per one standard deviation
difference in the common carotid artery IMT was
1.32 (95% CI: 1.27–1.38), and per 0.10-mm differ-
ence it was 1.18 (95% CI: 1.16–1.21). Age distribu-
tion, carotid segment deﬁnition and protocol for
measuring IMT represented sources of heterogeneity
among the studies. Based on this meta-analysis, the
authors concluded that carotid IMT is a strong and
valid predictor of vascular events (35).
Prevention and treatment of
subclinical atherosclerosis
Atherosclerosis is a chronic and progressive disease
whose optimal prevention requires lifelong attention
to diet and exercise, smoking abstinence, and aggres-
sive risk factor identiﬁcation and treatment. National
and international treatment guidelines recognise the
importance of LDL-C in driving atherogenesis and
CHD risk and recommend stratiﬁed target LDL-C
levels for reducing this risk. When diet and exercise
alone are not sufﬁcient for achieving the LDL-C goal,
statin therapy is most frequently initiated. Numerous
studies have shown that statins not only reduce
CHD morbidity and mortality but also decrease the
rate of atherosclerotic disease progression and, under
some circumstances, can even induce the regression
of atherosclerotic plaque (36,49–53).
Patients With CHD
In studies using B-mode ultrasonography in patients
with CHD, statin therapy slows the rate of athero-
sclerosis progression in the carotid artery. In an early
study, pravastatin 40 mg⁄day reduced progression of
atherosclerosis by 35% in the common carotid artery
over a 3-year period; the carotid IMT increased by a
mean of 0.029 mm⁄year with pravastatin compared
with 0.046 mm⁄year with placebo (p = 0.03) (49).
However, pravastatin did not signiﬁcantly affect the
change in IMT at the carotid bifurcation or internal
carotid artery. In a more recent study, intensive ther-
apy with atorvastatin 80 mg⁄day, which resulted in a
mean LDL-C of 1.97 mmol⁄l (76 mg⁄dl), reduced
carotid IMT by 0.034 mm over 12 months, whereas
the carotid IMT increased by 0.025 mm in the group
assigned to moderate lipid lowering with pravastatin
40 mg⁄day [achieved LDL-C, 2.84 mmol⁄l
(110 mg⁄dl)] (36).
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dramatic results, and the clinical beneﬁts were
related, once again, to the intensity of statin therapy.
The Reversal of Atherosclerosis with Aggressive Lipid
Lowering trial (50) compared moderate lipid lower-
ing with pravastatin 40 mg and intensive lipid lower-
ing with atorvastatin 80 mg in 654 patients with
angiographic evidence of luminal narrowing ‡ 20%
in at least one coronary vessel. LDL-C was lowered
to a mean of 2.84 mmol⁄l (110 mg⁄dl) with pravast-
atin and 2.04 mmol⁄l (79 mg⁄dl) with atorvastatin.
Intensive therapy with atorvastatin prevented pro-
gression of coronary atherosclerosis; the atheroma
volume was essentially unchanged ()0.4%) over the
18-month follow-up, whereas it increased by 2.7% in
the pravastatin group (p = 0.02) (50). In A Study to
Evaluate the Effect of Rosuvastatin on Intravascular
Ultrasound-Derived Coronary Atheroma Burden
(51), intensive therapy with rosuvastatin 40 mg⁄day,
which achieved a mean LDL-C of 1.58 mmol⁄l
(61 mg⁄dl), signiﬁcantly reduced the percent ather-
oma volume by 0.98% compared with baseline over
2 years (p < 0.001). For the secondary end-point of
median change in the most diseased 10-mm subseg-
ment of a target coronary vessel, plaque volume
decreased by 5.6% (p < 0.001). This ﬁnding suggests
that intensive statin therapy designed to achieve very
low LDL-C levels can in fact reverse coronary athero-
sclerosis to some degree.
Patients with subclinical atherosclerosis
Aggressive statin therapy reduces carotid IMT in
patients with familial hypercholesterolaemia, a popu-
lation at high risk of premature CHD. In the 2-year
Atorvastatin versus Simvastatin on Atherosclerosis
Progression trial (52), a randomised, controlled trial
of 325 patients with familial hypercholesterolaemia,
atorvastatin 80 mg⁄day reduced the mean carotid
IMT from baseline by 0.031 mm; this differed signiﬁ-
cantly from the mean 0.036-mm increase seen with
simvastatin 40 mg⁄day (p = 0.0005). In the atorvasta-
tin group, mean decreases in IMT from baseline were
observed in the common carotid artery ()0.041 mm,
p = 0.001) and internal carotid artery ()0.032 mm,
p = 0.03), but not at the carotid bulb ()0.022 mm,
p = 0.37) (52). The impact of aggressive LDL-C low-
ering on carotid IMT was explored in the Ezetimibe
and Simvastatin in Hypercholesterolemia Enhances
Atherosclerosis Regression trial (54). In this 2-year
study, 725 patients with familial hypercholesterola-
emia were randomly allocated to treatment with sim-
vastatin 80 mg plus ezetimibe 10 mg or to simvastatin
80 mg alone. Preliminary results announced in Janu-
ary 2008 showed that, although there was a signiﬁ-
cantly greater reduction in LDL-C with combination
therapy vs. simvastatin alone (58% vs. 41%;
p < 0.01), this reduction was not associated with a
difference in slowing atherosclerosis progression over
2 years: carotid IMT increased by 0.0111 mm in the
combination therapy group and by 0.0058 mm in the
monotherapy group (p = 0.29) (55).
Aggressive statin therapy with rosuvastatin was
recently shown to arrest atherosclerotic disease pro-
gression. The Measuring Effects on Intima-Media
Thickness: an Evaluation of Rosuvastatin (METEOR)
study (53) enrolled 984 persons with age as the only
CHD risk factor or a 10-year Framingham Risk Score
< 10%, modest carotid IMT thickening (1.2–
3.5 mm), and elevated LDL-C [mean, 3.98 mmol⁄l
(154 mg⁄dl)]. Subjects were randomly assigned to
rosuvastatin 40 mg⁄day or placebo for 2 years. LDL-
C was reduced to a mean of 2.02 mmol⁄l (78 mg⁄dl)
in the rosuvastatin group and was essentially
unchanged in the placebo group. Over the 2-year
study period, rosuvastatin slowed the progression of
maximum carotid IMT, measured by B-mode ultra-
sound at 12 carotid sites, compared with placebo
[)0.0014 mm⁄year (95% CI: )0.0041 to +0.0014) vs.
+0.0131 mm⁄year (0.0087–0.0174), p < 0.001]. Com-
parable results favouring rosuvastatin were seen when
maximum IMT was measured in the common caro-
tid artery ()0.0038 vs. +0.0084 mm⁄year, p < 0.001),
carotid bulb ()0.0040 vs. +0.172 mm⁄year,
p < 0.001) and internal carotid artery (+0.0039 vs.
+0.0145 mm⁄year, p = 0.02) (53). Thus, METEOR
showed that in a low-risk population with evidence
of subclinical atherosclerosis, rosuvastatin either sig-
niﬁcantly reversed (in common carotid artery) or
stopped or signiﬁcantly arrested (in the other seg-
ments) the progression of atherosclerosis. Based on
the results of METEOR, the US Food and Drug
Administration in 2007 approved an indication for
the use of rosuvastatin as an adjunct to diet in slow-
ing the progression of atherosclerosis (56).
The effect of conservative vs. aggressive statin treat-
ment on carotid atherosclerosis was also evaluated by
high-resolution MRI (57). A total of 43 subjects with
evidence of carotid stenosis measured by ultrasound
or evidence of a plaque with a lipid-rich necrotic core
identiﬁed by MRI were enrolled in the Outcome of
Rosuvastatin Treatment on Carotid Artery Atheroma:
a Magnetic Resonance Imaging Observation (57) and
were treated with rosuvastatin 5 or 40 mg. After
2 years, the median per cent change in carotid wall
volume was +0.5% in the low-dose rosuvastatin
group and )1.4% in the high-dose group. Subjects
with carotid wall regression achieved lower mean
LDL-C levels than those with atherosclerosis progres-
sion [1.78 vs. 2.17 mmol⁄l (69 vs. 84 mg⁄dl)]. Nota-
bly, rosuvastatin 5 and 40 mg reduced the size of the
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in the subset of subjects with such plaques at baseline,
and nearly all patients showed regression from base-
line. Moreover, no patients developed a new plaque
with a lipid-rich necrotic core during treatment (57).
Thus, treatment with rosuvastatin arrested progres-
sion of atherosclerosis and caused regression of the
lipid-rich necrotic core in plaque.
Several studies have compared the effects of inten-
sive vs. conventional statin therapy on coronary
artery calciﬁcation measured by EBCT in subjects
with subclinical atherosclerosis (58,59). Over a 1-year
period, coronary artery calciﬁcation progressed simi-
larly, regardless of whether subjects received a low or
high dose of statin therapy and independently of the
achieved serum LDL-C level. These ﬁndings suggest
either that (i) atherosclerotic calcium deposition may
not be reversible by statin therapy or (ii) a 12-month
follow-up period may be too short to demonstrate a
beneﬁcial effect of statins on coronary artery calciﬁ-
cation.
Key questions and future directions
Who should be screened, and which tests are
appropriate?
As the technology for early diagnosis of atherosclero-
sis advances and becomes available for clinical use, a
key question is who should be screened. In 2006, the
American Heart Association Committee on Cardio-
vascular Imaging and Intervention issued a scientiﬁc
statement on the clinical utility of detecting calciﬁed
plaque and the appropriate use of CT in a variety of
clinical situations (60). A clinical expert consensus
statement by the American College of Cardiology
and the American Heart Association suggests that
this relatively inexpensive technique may be appro-
priate for patients at intermediate risk based on their
Framingham score, if there is a likelihood that a high
coronary artery calcium score may reclassify these
patients as higher risk and therefore requiring more
intensive treatment (61). Although recommendations
for the appropriate use of cardiovascular imaging in
primary prevention are limited in number, many car-
diologists today, in order not to underestimate risk,
are using additional imaging modalities in asymp-
tomatic patients with a strong family history of car-
diovascular disease and⁄or a 10-year Framingham
risk of ‡ 20%.
Should patients with subclinical atherosclerosis
be treated?
In several early studies, reductions in surrogate out-
comes with lipid-lowering treatment appeared to
correlate highly with reductions in cardiovascular
events (49,62,63). However, although some trials
have shown trends toward improved clinical out-
comes following treatment for asymptomatic athero-
sclerosis (36,64), no imaging study to date has been
designed or powered to prospectively correlate
regression or lack of progression of atherosclerosis
with reduction in risk for clinical events. The Ameri-
can College of Cardiology⁄American Heart Associa-
tion consensus document on coronary artery calcium
correlates pooled data for clinical outcomes with cor-
onary artery calcium scores (61). The fact that per-
sons with low coronary artery calcium scores have a
very low risk for ‘hard’ CHD events (49
events⁄11,815, 0.4%) corroborates a correlation
between atherosclerosis and clinical events. There is
currently no position paper on carotid IMT, and we
do not know the extent to which magnitude of
change (increase, stabilisation or decrease) in carotid
IMT correlates with disease outcomes.
The clinical signiﬁcance of reducing the volume of
atherosclerotic lesions using lipid-lowering treatment
has not been established, and studies using surrogate
end-points have not yet evaluated the magnitude of
effects on clinical end-points. For example, we do
not yet know how much plaque reduction would be
required to lower cardiovascular risk by 10%, 20%
or more. We do know that in a diffuse condition
such as atherosclerosis, aggressive and comprehensive
risk factor management provides equal efﬁcacy in
reducing risk for ACS compared with prophylactic
percutaneous transluminal angioplasty with stenting
(65). Therefore, if cardiovascular imaging establishes
the presence of atherosclerotic disease in asymptom-
atic patients, many clinical trials support the use of
intervention with statin therapy to reduce the rate of
disease progression. Pending future randomised clini-
cal trials designed to correlate reductions in athero-
sclerosis with clinical outcomes in persons without
CHD but with evidence of subclinical atherosclerosis,
the majority of clinicians would evaluate global risk
factor burden in these individuals and treat them as
high-risk patients in an effort to optimally impact
the course of disease.
Conclusions
Atherosclerosis is a chronic and progressive disease
that causes substantial cardiovascular morbidity and
mortality. Although often detected when patients
ﬁrst experience a major cardiovascular event, several
techniques can be used to identify atherosclerosis
when it is still in its subclinical stages. Reducing ath-
erogenic lipoprotein burden with statin therapy is
associated with signiﬁcant changes in rates of coro-
nary and carotid atherosclerosis disease progression.
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with aggressive statin therapy to lower LDL-C. As
shown in the Pravastatin or Atorvastatin Evaluation
and Infection Therapy – Thrombolysis in Myocardial
Infarction 22 trial (66), such aggressive LDL-C low-
ering is also associated with signiﬁcantly greater
reductions in risk for acute cardiovascular events,
need for revascularisation and hospitalisation for
unstable angina pectoris compared with more mod-
erate lipid lowering. Other recent clinical outcome
trials (67,68) also underscore the considerable need
for aggressive lipid lowering with statins in patients
with established atherosclerotic disease.
Acknowledgement
The author wishes to thank Ruth Sussman, PhD, of
Landmark Programs, Inc., for editorial assistance in
the preparation of this manuscript.
References
1 American Heart Association. Heart Disease and Stroke Statistics:
2007 Update. Dallas, TX: American Heart Association, 2007.
2 CHD Statistics Fact Sheet 2008: United Kingdom. http://
www.ws3.heartstats.web.baigent.net/datapage.asp?id=6799 (Accessed
May 2008).
3 McNamara JJ, Molot MA, Stremple JF et al. Coronary artery dis-
ease in combat casualties in Vietnam. JAMA 1971; 216: 1185–7.
4 Newman WP III, Freedman DS, Voors AW et al. Relation of serum
lipoprotein levels and systolic blood pressure to early atherosclerosis:
the Bogalusa Heart Study. N Engl J Med 1986; 314: 138–44.
5 PDAY Research Group. Relationship of atherosclerosis in young
men to serum lipoprotein cholesterol concentrations and smoking:
a preliminary report from the Pathobiological Determinants of
Atherosclerosis in Youth (PDAY) Research Group. JAMA 1990;
264: 3018–24.
6 Newman AB, Arnold AM, Naydeck BL et al. ‘Successful aging’:
effect of subclinical cardiovascular disease. Arch Intern Med 2003;
163: 2315–22.
7 Fuster V. Mechanism leading to myocardial infarction: insights
from studies of vascular biology. Circulation 1994; 90: 2126–46.
8 Ross R. Atherosclerosis: an inﬂammatory disease. N Engl J Med
1999; 340: 115–26.
9 Zaman AG, Helft G, Worthley SG et al. The role of plaque rupture
and thrombosis in coronary artery disease. Atherosclerosis 2000;
149: 251–66.
10 Hansson GK. Inﬂammation, atherosclerosis, and coronary artery
disease. N Engl J Med 2005; 352: 1685–95.
11 Rao RM, Yang L, Garcia-Cardena G et al. Endothelial-dependent
mechanisms of leukocyte recruitment to the vascular wall. Circ Res
2007; 101: 234–47.
12 Virmani R, Kolodgie FD, Burke AP et al. Atherosclerotic plaque
progression and vulnerability to rupture: angiogenesis is a source
of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005; 25:
2054–61.
13 Libby P, Theroux P. Pathophysiology of coronary artery disease.
Circulation 2005; 111: 3481–8.
14 Davies JR, Rudd JH, Weissberg PL. Molecular and metabolic imag-
ing of atherosclerosis. J Nucl Med 2004; 45: 1898–907.
15 Burke AP, Kolodgie FD, Farb A et al. Healed plaque ruptures and
sudden coronary death: evidence that subclinical rupture has a role
in plaque progression. Circulation 2001; 103: 934–40.
16 Grundy SM. Coronary plaque as a replacement for age as a risk
factor in global risk assessment. Am J Cardiol 2001; 88 (Suppl.
2A): 8E–11E.
17 Devaraj S, Rogers J, Jialal I. Statins and biomarkers of inﬂamma-
tion. Curr Atheroscler Rep 2007; 9: 33–41.
18 Tuzcu EM, Nicholls SJ. Statins: targeting inﬂammation by lowering
low-density lipoprotein? J Am Coll Cardiol 2007; 49: 2010–2.
19 Khera A, de Lemos JA, Peshock RM et al. Relationship between
C-reactive protein and subclinical atherosclerosis: the Dallas
Heart Study. Circulation 2006; 113: 38–43.
20 Schillinger M, Exner M, Mlekusch W et al. Inﬂammation and Car-
otid Artery – Risk for Atherosclerosis Study (ICARAS). Circulation
2005; 111: 2203–9.
21 Ridker PM. C-reactive protein and the prediction of cardiovascular
events among those at intermediate risk: moving an inﬂammatory
hypothesis toward a consensus. J Am Coll Cardiol 2007; 49: 2129–
38.
22 Ridker PM, on behalf of the JUPITER Study Group. Rosuvastatin
in the primary prevention of cardiovascular disease among patients
with low levels of low-density lipoprotein cholesterol and elevated
high-sensitivity C-reactive protein. Circulation 2003; 108: 2292–7.
23 Kuller L, Borhani N, Furberg C et al. Prevalence of subclinical ath-
erosclerosis and cardiovascular disease and association with risk
factors in the Cardiovascular Health Study. Am J Epidemiol 1994;
139: 1164–79.
24 Jaffer FA, O’Donnell CJ, Larson MG et al. Age and sex distribution
of subclinical aortic atherosclerosis: a magnetic resonance imaging
examination of the Framingham Heart Study. Arterioscler Thromb
Vasc Biol 2002; 22: 849–54.
25 Sutton-Tyrell K, Kuller LH, Matthews KA et al. Subclinical athero-
sclerosis in multiple vascular beds: an index of atherosclerotic bur-
den evaluated in postmenopausal women. Atherosclerosis 2002;
160: 407–16.
26 Michos ED, Vasamreddy CR, Becker DM et al. Women with a low
Framingham risk score and a family history of premature coronary
heart disease have a high prevalence of subclinical coronary athero-
sclerosis. Am Heart J 2005; 150: 1276–81.
27 Lee TC, O’Malley PG, Feuerstein I et al. The prevalence and sever-
ity of coronary artery calciﬁcation on coronary artery computed
tomography in black and white subjects. J Am Coll Cardiol 2003;
41: 39–44.
28 Nasir K, Santos RD, Tufail K et al. High-normal fasting glucose in
non-diabetic range is associated with increased coronary artery cal-
cium burden in asymptomatic men. Atherosclerosis 2007; 195:
e155–60; Epub 2 July 2007.
29 Tzou WS, Douglas PS, Srinivasan SR et al. Increased subclinical
atherosclerosis in young adults with metabolic syndrome: the Bog-
alusa Heart Study. J Am Coll Cardiol 2005; 46: 457–63.
30 McNeill AM,Rosamond WD,Girman CJetal.Prevalence ofcoronary
heart disease and carotid arterial thickening in patients with the meta-
bolic syndrome (the ARIC Study).Am JCardiol2004; 94: 1249–54.
31 Ingelsson E, Sullivan LM, Murabito JM et al. Prevalance and prog-
nostic impact of subclinical cardiovascular disease in individuals
with the metabolic syndrome and diabetes. Diabetes 2007; 56:
1718–26.
32 Schurgin S, Rich S, Mazzone T. Increased prevalence of signiﬁcant
coronary artery calciﬁcation in patients with diabetes. Diabetes
Care 2001; 24: 335.
33 Zeina AR, Odeh M, Rosenschein U et al. Coronary artery disease
among asymptomatic diabetic and nondiabetic patients undergoing
coronary computed tomography angiography. Coron Artery Dis
2008; 19: 37–41.
34 Heiss G, Sharett AR, Barnes R et al. Carotid atherosclerosis mea-
sured by B-mode ultrasound in populations: associations with car-
diovascular risk factors in the ARIC study. Am J Epidemiol 1991;
134: 250–6.
35 Lorenz MW, Markus HS, Bots ML et al. Prediction of clinical car-
diovascular events with carotid intima-media thickness: a system-
atic review and meta-analysis. Circulation 2007; 115: 459–67.
Subclinical atherosclerosis 1253
ª 2008 The Author
Journal compilation ª 2008 Blackwell Publishing Ltd Int J Clin Pract, August 2008, 62, 8, 1246–125436 Taylor AJ, Kent SM, Flaherty PJ et al. ARBITER: Arterial Biology
for the Investigation of the Treatment Effects of Reducing Choles-
terol: a randomized trial comparing the effects of atorvastatin and
pravastatin on carotid intimal medial thickness. Circulation 2002;
106: 2055–60.
37 Fayad ZA, Fuster V. The human high-risk plaque and its detection
by magnetic resonance imaging. Am J Cardiol 2001; 88 (Suppl.):
42E–5E.
38 Chu B, Hatsukami TS, Polissar NL et al. Determination of carotid
artery atherosclerotic lesion type and distribution in hypercholes-
terolemic patients with moderate carotid stenosis using noninva-
sive magnetic resonance imaging. Stroke 2004; 35: 2444–8.
39 Schmermund A, Mohlenkamp S, Erbel R. Coronary artery calcium
and its relationship to coronary artery disease. Cardiol Clin 2003;
21: 521–34.
40 Shaw LJ, Raggi P, Schisterman E et al. Prognostic value of cardiac
risk factors and coronary artery screening for all-cause mortality.
Radiology 2003; 223: 826–33.
41 Kondos GT, Hoff JA, Sevrukov A et al. Electron-beam tomography
coronary artery calcium and cardiac events: a 37-month follow-up
of 5635 initially asymptomatic low- to intermediate-risk adults.
Circulation 2003; 107: 2571–6.
42 Greenland P, LaBree L, Azen SP et al. Coronary artery calcium
score combined with Framingham score for risk prediction in
asymptomatic individuals. JAMA 2004; 291: 210–5.
43 Detrano RC, Anderson M, Nelson J et al. Coronary calcium
measurements: effect of CT scanner type and calcium measure
on rescan reproducibility: MESA study. Radiology 2005; 236:
477–84.
44 Achenbach S. Current and future status on cardiac computed
tomography imaging for diagnosis and risk stratiﬁcation. J Nucl
Cardiol 2005; 12: 703–13.
45 Little WC, Constantinescu M, Applegate RJ et al. Can coronary
angiography predict the site of a subsequent myocardial infarction
in patients with mild-to-moderate coronary artery disease? Circula-
tion 1988; 78: 1157–66.
46 DeMaria AN, Narula J, Mahmud E et al. Imaging vulnerable pla-
que by ultrasound. J Am Coll Cardiol 2006; 47: C32–9.
47 Baldassarre D, Amato M, Pustina L et al. Measurement of carotid
intima-media thickness in dyslipidemic patients increases the
power of traditional risk factors to predict cardiovascular events.
Atherosclerosis 2007; 191: 403–8.
48 Simon A, Chironi G, Levenson J. Performance of subclinical arte-
rial disease detection as a screening test for coronary heart disease.
Hypertension 2006; 48: 392–6.
49 Crouse JR III, Byington RP, Bond MG et al. Pravastatin, lipids,
and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol
1995; 75: 455–9.
50 Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive
compared with moderate lipid-lowering therapy on progression of
coronary atherosclerosis: a randomized controlled trial. JAMA
2004; 291: 1071–80.
51 Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity
statin therapy on regression of coronary atherosclerosis: the
ASTEROID trial. JAMA 2006; 295: 1556–65.
52 Smilde TJ, van Wissen S, Wollersheim H et al. Effect of aggressive
versus conventional lipid lowering on atherosclerosis progression
in familial hypercholesterolemia (ASAP): a prospective, random-
ized, double-blind trial. Lancet 2001; 357: 577–81.
53 Crouse JR III, Raichlen JS, Riley WA et al., for the METEOR Study
Group. Effect of rosuvastatin on progression of carotid intima-
media thickness in low-risk individuals with subclinical atheroscle-
rosis: the METEOR trial. JAMA 2007; 297: 1344–53.
54 Kastelein JJP, Sager PT, de Groot E et al. Comparison of ezetimibe
plus simvastatin versus simvastatin monotherapy on atherosclerosis
progression in familial hypercholesterolemia: design and rationale
of the Ezetimibe and Simvastatin in Hypercholesterolemia
Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart
J 2005; 149: 234–9.
55 Schering-Plough Web Site. Merck ⁄ Schering-Plough Pharmaceuticals
Provides Results of the ENHANCE Trial (14 January 2008, News
Release). http://www.schering-plough.com/schering_plough/news/
release.jsp?releaseID1095943 (accessed March 2008).
56 Crestor (Rosuvastatin Calcium) Prescribing Information. Wilming-
ton, DE: AstraZeneca Pharmaceuticals LP, 2007.
57 Hatsukami TS, Zhao X-Q, Kraiss LW et al. Assessment of rosu-
vastatin treatment on carotid atherosclerosis in moderately hyper-
cholesterolemic subjects using high-resolution magnetic resonance
imaging. Eur Heart J 2005; 26: 626–7; Abstract 3700.
58 Raggi P, Davidson M, Callister TQ et al. Aggressive versus moder-
ate lipid-lowering therapy in hypercholesterolemic postmenopausal
women: beyond endorsed lipid lowering with EBT scanning
(BELLES). Circulation 2005; 112: 563–71.
59 Schmermund A, Achenbach S, Budde T et al. Effect of intensive
versus standard lipid-lowering treatment with atorvastatin on the
progression of calciﬁed coronary atherosclerosis over 12 months: a
multicenter, randomized, double-blind trial. Circulation 2006; 113:
427–37.
60 Budoff MJ, Achenbach S, Blumenthal RS et al. Assessment of coro-
nary artery disease by cardiac computed tomography: a scientiﬁc
statement from the American Heart Association Committee on
Cardiovascular Imaging and Intervention, Council on Cardiovascu-
lar Radiology and Intervention, and Committee on Cardiac Imag-
ing, Council on Clinical Cardiology. Circulation 2006; 114: 1761–
91.
61 Greenland P, Bonow RO, Brundage BH et al. ACCF ⁄AHA 2007
clinical expert consensus document on coronary artery calcium
scoring by computed tomography in global cardiovascular risk
assessment and in evaluation of patients with chest pain: a report
of the American College of Cardiology Foundation Clinical Expert
Consensus Task Force developed in collaboration with the Society
of Atherosclerosis Imaging and Prevention and the Society of Car-
diovascular Computed Tomography. J Am Coll Cardiol 2007; 49:
378–402.
62 Furberg CD, Adams HP Jr, Applegate WB et al. Effect of lovastatin
on early carotid atherosclerosis and cardiovascular events. Asymp-
tomatic Carotid Artery Progression Study (ACAPS) Research
Group. Circulation 1994; 90: 1679–87.
63 Salonen R, Nyysso ¨nen K, Porkkala E et al. Kuopio Atherosclerosis
Prevention Study (KAPS): a population-based primary preventive
trial of the effects of LDL lowering on atherosclerotic progression
in carotid and femoral arteries. Circulation 1995; 92: 1758–64.
64 Taylor AJ, Sullenberger LE, Lee HJ et al. Arterial Biology for the
Investigation of the Treatment Effects of Reducing Cholesterol
(ARBITER) 2: a double-blind, placebo-controlled study of
extended-release niacin on atherosclerosis progression in secondary
prevention patients treated with statins. Circulation 2004; 110:
3512–7.
65 Boden WE, O’Rourke RA, Teo KK et al., for the COURAGE Trial
Research Group. Optimal medical therapy with or without PCI for
stable coronary disease. N Engl J Med 2007; 356: 1503–16.
66 Cannon CP, Braunwald E, McCabe CH et al., for the Pravastatin
or Atorvastatin Evaluation and Infection Therapy – Thrombolysis
in Myocardial Infarction 22 Investigators. Intensive versus moder-
ate lipid lowering with statins after acute coronary syndromes. N
Engl J Med 2004; 350: 1495–504.
67 LaRosa JC, Grundy SM, Waters DD et al., for the Treating to New
Targets (TNT) Investigators. Intensive lipid lowering with atorvast-
atin in patients with stable coronary disease. N Engl J Med 2005;
352: 1425–35.
68 Pedersen TR, Faergeman O, Kastelein JJ et al., for the Incremental
Decrease in End Points Through Aggressive Lipid Lowering
(IDEAL) Study Group. High-dose atorvastatin vs usual-dose sim-
vastatin for secondary prevention after myocardial infarction: the
IDEAL study: a randomized controlled trial. JAMA 2005; 294:
2437–45.
Paper received February 2008, accepted April 2008
1254 Subclinical atherosclerosis
ª 2008 The Author
Journal compilation ª 2008 Blackwell Publishing Ltd Int J Clin Pract, August 2008, 62, 8, 1246–1254